Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
收藏Protein Data Bank Japan2024-10-23 更新2026-03-21 收录
下载链接：
https://pdbj.org/mine/summary/6usx
下载链接
链接失效反馈官方服务：
资源简介：
Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer Descriptor: 1-{4-[2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl}propan-1-one, GTPase KRas, GUANOSINE-5'-DIPHOSPHATE, ... Authors: Vigers, G.P, Smith, D.J. Deposit date: 2019-10-28 Release date: 2020-04-22 Last modified: 2024-10-23 Method: X-RAY DIFFRACTION (2.27 Å) Cite: Identification of the Clinical Development CandidateMRTX849, a Covalent KRASG12CInhibitor for the Treatment of Cancer. J.Med.Chem., 63, 2020
创建时间：
2019-10-28
